NCT06216756 · AlloSource
Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment of Osteochondral Lesions in the Knee
What this study is about
The primary objective of this study is to obtain evidence of the effectiveness of Cryopreserved Osteochondral Allograft Core in the treatment of osteochondral lesions on the femoral condyle.
View original scientific description
The primary objective of this study is to obtain evidence of the effectiveness of Cryopreserved Osteochondral Allograft Core in the treatment of osteochondral lesions on the femoral condyle.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Patients are ≥12 years and ≤ 60 years of age at the time of surgery.
- Symptomatic patient presenting with moderate to severe pain in the index knee - unresponsive to conservative treatment (i.e., medication, bracing, physical therapy) and/or previous surgical intervention OR unsalvageable lesion that requires transplantation at the discretion of the treating physician.
- Radiographically diagnosed, by MRI or CT scans, or through arthroscopy, to have a cartilage defect on the femoral condyle between 0.9-8.0 cm2 in size.
- Will be having an osteochondral transplant procedure.
- Has a mechanically stable knee or can be mechanically stabilized in the same procedure.
- Has a normally aligned knee as confirmed by anatomic comparison to contralateral limb, or \<5° varus or valgus malalignment that has been corrected or will be corrected in same procedure.
- Ipsilateral knee compartment has intact menisci or requires partial meniscectomy ≤ 50% resulting in stable menisci.
- Confirmation MRI, CT scan, or arthroscopy obtained pre-operatively within 90 days of surgery
- Willingness to follow standardized rehabilitation procedures.
- Has the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol.
Exclusion criteria
- Bipolar articular cartilage involvement (kissing lesions) of the ipsilateral compartment (i.e., \> than ICRS Grade 2 on the opposing articular surface).
- Has had a prior osteochondral allograft transplant procedure in the same knee.
- Will be receiving a meniscus allograft transplantation in the same procedure.
- Body Mass Index (BMI)of ≥ 35 kg/m2.
- Active malignancy: undergoing treatment for tumor or boney traumatic injury or a history of any invasive malignancy (except non-melanoma skin cancer) unless the patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years.
- Clinical and/or radiographic disease in the affected joint that includes generalized osteoarthritis, gout or a history of gout or pseudo-gout.
- Active local microbial infection or a systemic infection, including HIV, syphilis, Hepatitis B or Hepatitis C.
- Currently immunologically suppressed or immunocompromised, or a medical condition requiring radiation and/or chemotherapy.
- Unstable cardiovascular, renal, hepatic, endocrine and/or pulmonary disease, cancer, or uncontrolled diabetes.
- Has a history of any inflammatory joint arthropathy.
- Currently using/chronic on oral corticosteroids.
- Received interarticular corticosteroid injection ≤ 90 days prior to surgery.
- Received hyaluronic acid injections into the joint space ≤ 45 days prior to surgery.
- Is a female patient who is pregnant.
- Physically or mentally compromised (i.e., being currently treated for a psychiatric disorder, senile dementia, Alzheimer's disease) in a manner that would compromise his/her ability to participate in the clinical study.
- Has a history of substance abuse- (including but not limited to recreational drugs, alcohol) or has been treated in the last 6 months before enrollment for alcohol and/or drug abuse in an in-patient substance abuse program.
- Patients who, in the opinion of the Investigator, would not be able or willing to comply with the protocol.
- Is currently involved in a study of another investigational product for similar purpose or has been in the previous 90 days.
- Has any contraindications for MRI.
- Is having the procedure as part of a Worker's Compensation claim.
- Is a ward of the state, prisoner, or transient.
Where
- Phoenix, Arizona
- Los Angeles, California
- Redwood City, California
- San Francisco, California
- Aurora, Illinois
- Lexington, Kentucky
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Nov 25, 2025 · Source of record for eligibility and locations